{"brief_title": "A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)", "brief_summary": "This study is to assess the safety and tolerability of MK0217 being evaluated to treat women with postmenopausal osteoporosis.", "condition": ["Postmenopausal Osteoporosis"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["MK0217, alendronate sodium/Duration of Treatment: 6 months", "Comparator: placebo / Duration of Treatment: 6 months"], "criteria": "Inclusion Criteria: - Women with postmenopausal osteoporosis Exclusion Criteria: - High risk for fractures - Esophageal abnormalities - Upper gastrointestinal symptoms that are not relieved with medication - Metabolic bone disease (example - vitamin D deficiency) - Medications that would affect the breakdown or build-up of bone", "gender": "Female", "minimum_age": "25 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Osteoporosis", "Osteoporosis, Postmenopausal", "Alendronate"], "id": "NCT00092027"}